Preliminary clinical outcomes of irreversible electroporation in the management of prostatic hyperplasia

This study evaluates the efficacy and safety of IRE (irreversible electroporation) ablation in the management of BPH (benign prostatic hyperplasia). Clinical data from 9 patients with prostate hyperplasia who underwent IRE treatment between September 2022 and August 2024 were retrospectively analyzed. Outcomes were assessed to determine the effectiveness and safety of IRE in ablating hyperplastic prostate tissue. IRE ablation was successfully performed in all patients. Postoperative assessments showed no significant reduction in prostate volume compared to preoperative measurements, This might be related to the mechanism of action of IRE. However, maximum urine flow rate significantly increased, and PVR (residual urine volume) significantly decreased. Additionally, the IPSS (International Prostate Symptom Score) showed a statistically significant improvement (P < .05) compared to preoperative values. Sexual function remained largely unaffected. Adverse reactions were reported in 2 cases (22%). IRE has demonstrated better efficacy and an acceptable safety profile, accompanied by a low incidence of postoperative complications in the treatment of BPH. This technique provides a novel alternative for clinical management. However, due to the limited sample size in this study, further validation through long-term follow-up studies and expanded cohorts is necessary to confirm its sustained effectiveness.